Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193068 | 0.83 | HDAC6 (0.46) | HDAC6LOXL2TRPV1ALOX15HTT | |
| SCHEMBL13539291 | 0.66 | PIK3CA (0.54) | HTTSMN1; SMN2RAB9ANPC1GAA | |
| SCHEMBL10254309 | 0.66 | ALDH1A1 (0.57) | TRPV1HTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL489036 | 0.64 | TRPV1 (0.48) | HDAC6LOXL2TRPV1ALOX15HTT | |
| SCHEMBL10268888 | 0.63 | MAPT (0.45) | HDAC6LOXL2TRPV1ALOX15HTT | |
| SCHEMBL19058424 | 0.63 | HDAC6 (1.00) | HDAC6TRPV1 | |
| SCHEMBL23874614 | 0.62 | RAB9A (0.41) | SMN1; SMN2RAB9ANPC1GAAMAPK1 | |
| SCHEMBL14327114 | 0.62 | SMN1; SMN2 (0.65) | ALOX15SMN1; SMN2GAAHPGD | |
| SCHEMBL7435843 | 0.61 | UBE2T (0.56) | ALOX15HTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL9763984 | 0.61 | HDAC6 (0.43) | HDAC6LOXL2ALOX15HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | HDAC6 1276/4885LOXL2 1889/4885TRPV1 226/4885 |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | HRH3, HRH4, HRH2 | HDAC6 1276/4885LOXL2 1889/4885TRPV1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.